A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Anova Innovation Limited
Genmab
Actuate Therapeutics Inc.
ImmunityBio, Inc.
Engeneic Pty Limited
FutureGen Biopharmaceutical (Beijing) Co., Ltd
NovoCure Ltd.
Ascentage Pharma Group Inc.
NovoCure Ltd.
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
Genfleet Therapeutics (Shanghai) Inc.
Laekna Limited
ProDa BioTech, LLC
Trishula Therapeutics, Inc.
ImmunityBio, Inc.
Nelum Corp
Purple Biotech Ltd.
Sumitomo Pharma America, Inc.
Corcept Therapeutics
Jazz Pharmaceuticals
CSPC Ouyi Pharmaceutical Co., Ltd.